Brokerages Set Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) PT at $61.60

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have received an average recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $61.60.

Several equities analysts recently issued reports on SUPN shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Stifel Nicolaus boosted their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. TD Cowen upped their price objective on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Bank of America assumed coverage on Supernus Pharmaceuticals in a report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st.

Insiders Place Their Bets

In related news, VP Padmanabh P. Bhatt sold 710 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the sale, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. This trade represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the sale, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. This represents a 56.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 8.80% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC grew its holdings in shares of Supernus Pharmaceuticals by 92.4% during the 2nd quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 1,479 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Supernus Pharmaceuticals by 8.8% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock worth $453,000 after purchasing an additional 1,161 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Supernus Pharmaceuticals by 30.4% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock worth $2,696,000 after purchasing an additional 19,949 shares during the period. Ruffer LLP acquired a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $2,647,000. Finally, Castlekeep Investment Advisors LLC bought a new stake in Supernus Pharmaceuticals during the second quarter worth $1,263,000.

Supernus Pharmaceuticals Stock Up 4.6%

NASDAQ SUPN opened at $51.65 on Thursday. Supernus Pharmaceuticals has a twelve month low of $29.16 and a twelve month high of $57.65. The stock has a market cap of $2.96 billion, a P/E ratio of -151.91, a PEG ratio of 0.65 and a beta of 0.71. The company’s 50-day simple moving average is $49.12 and its 200 day simple moving average is $46.76.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.